Adverum Biotechnologies (ADVM) has released an update.
The Company unveiled promising preliminary data from the Phase 2 LUNA trial of Ixoberogene soroparvovec for wet age-related macular degeneration, showing both doses maintained visual acuity and anatomic outcomes, with significant reductions in the need for anti-VEGF injections. The trial, which built upon the OPTIC study, also found the treatment well-tolerated and responsive to corticosteroids, with no serious adverse events. Looking ahead, the Company anticipates further analysis in mid-2024 and the start of Phase 3 trials in the first half of 2025.
For further insights into ADVM stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
